CAMP4 Therapeutics (CAMP) Fundamental Analysis: Revenue, Earnings & Valuation

4.10 / 10

Netural

Fundamental rating is neutral with a 4.1/10 score. Revenue‑MV, Cash‑MV and inventory turnover are strong, while PB‑ROE and Asset‑MV are negative and fixed‑asset turnover is weak. YoY revenue growth is huge (436%), but overall quality remains defensive and average.

Analysis Checks(7/10)

Revenue-MV

Value-4.25

Score2/3

Weight19.30%

1M Return8.45%

Total operating revenue (YoY growth rate %)

Value436.50

Score3/3

Weight3.06%

1M Return1.54%

Inventory turnover ratio

Value103.94

Score3/3

Weight15.73%

1M Return6.74%

Gross profit margin (%)

Value100.00

Score2/3

Weight3.59%

1M Return1.69%

PB-ROE

Value-0.02

Score0/3

Weight7.92%

1M Return3.23%

Income tax / Total profit (%)

Value21.05

Score1/3

Weight-0.91%

1M Return-0.50%

Fixed assets turnover ratio

Value0.55

Score1/3

Weight-2.19%

1M Return-1.24%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight9.10%

1M Return4.32%

Asset-MV

Value-0.55

Score2/3

Weight30.42%

1M Return12.22%

Cash-MV

Value0.10

Score2/3

Weight13.98%

1M Return5.94%

Is CAMP undervalued or overvalued?

CAMP scores 4.10/10 on fundamentals and holds a Fair valuation at present. Backed by its -145.07% ROE, -2298.54% net margin, -2.88 P/E ratio, 4.85 P/B ratio, and 76.00% earnings growth, these metrics solidify its Netural investment rating.